Imagine a smart weather forecast, but for medical treatments. Instead of rain, it predicts if a patient will experience painful swelling in their arm after cancer therapy. It looks at a person's unique DNA and scans to help doctors tailor the treatment to avoid these complications.
Radiotherapy for breast cancer often causes severe side effects like arm lymphedema, but doctors currently lack a precise way to predict who will suffer these based on complex imaging and genetic data.
An AI-driven risk prediction tool and a user-friendly app platform that provides explainable risk scores to doctors and patients.
If you are a software vendor dealing with static treatment planning tools — this project developed an AI predictive model that integrates into existing commercial platforms to provide personalized risk scores. This adds a high-value diagnostic layer to your current product offering.
If you are a clinic dealing with unpredictable patient complications like arm lymphedema — this project developed a communication package and app that helps doctors and patients decide on prophylactic measures. This reduces unexpected side effects and improves patient quality of life.
If you are a manufacturer dealing with low adoption of preventative arm sleeves — this project developed a risk prediction tool that identifies high-risk patients. This provides a clinical justification for prescribing prophylactic sleeves earlier in the treatment process.
Based on available project data, specific pricing or cost structures are not mentioned. The project focuses on development and clinical validation.
Yes, the project specifically studies the transferability of these models to other cancers, such as prostate cancer, using transfer learning techniques.
Based on available project data, there are no specific details on licensing; however, the AI models are intended to be incorporated into an existing commercial radiotherapy software platform.
The project uses Federated Learning, which allows the AI to be trained on decentralized data from different centers without the data ever leaving its original secure location.
The project period runs from 2022-10-01 to 2027-09-30, suggesting the final validated results will be available toward the end of 2027.
The consortium is well-balanced for commercialization, featuring 12 partners across 6 countries. With a 33% industry ratio (4 industrial partners, including 4 SMEs), the project bridges the gap between academic research (4 universities, 4 research centers) and market application. The mix of expertise in health economics, psychology, and medical physics ensures the product is viable from both a clinical and financial perspective.
Contact the Athens University of Economics and Business Research Center
Contact us to explore licensing opportunities for the PRE-ACT AI models.
